The American Cancer Society published a report assessing the progress made in its 25-year goal to reduce cancer death rates by 50 percent. The report finds areas where progress was substantial, and others where it was not.
The NIH Clinical Center will be placed under a new system of governance, similar to that of hospitals.
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
The European Commission approved a variation to the terms of the Marketing Authorisation of eribulin for the treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy for advanced or metastatic disease.
AbbVie and CytomX Therapeutics Inc. entered into a collaboration to co-develop Probody Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Under the agreement, CytomX... […]
AstraZeneca and Foundation Medicine Inc. will collaborate to develop companion diagnostic assays to identify patients most likely to benefit from medicines within AstraZeneca’s oncology pipeline. AstraZeneca will utilize the Quality Systems Regulations-compliant version of Foundation Medicine’s comprehensive genomic profiling assay for solid tumors to enroll patients into clinical trials of therapies that target genomically driven... […]
The European Medicines Agency Committee for Medicinal Products for Human Use issued a positive opinion for Imbruvica (ibrutinib) for the treatment of adult patients with previously-untreated chronic lymphocytic leukemia. The positive CHMP recommendation follows the March 2016 FDA approval of Imbruvica for the first-line treatment of patients with CLL. If approved by the European Commission,... […]
THE AMERICAN CANCER SOCIETY and CVS Health announced a three-year, $3.6 million initiative to provide grants to 125 institutions of higher learning to help accelerate and expand the number of 100 percent smoke- and tobacco-free college and university campuses throughout the United States.
Health Canada approved Lynparza (olaparib) capsules as a maintenance treatment for patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. Lynparza is the first poly ADP-ribose polymerase inhibitor available in Canada, and has been granted the Health Canada Notice of Compliance with Conditions, based on... […]
THE CANADIAN CANCER CLINICAL TRIALS NETWORK unveiled a new national campaign to raise awareness of cancer clinical trials in Canada, ahead of International Clinical Trials Day on May 20. The Ask Me Campaign will be introduced at more than 60 cancer centers across Canada and include hospital staff wearing “Ask Me” buttons, as well as... […]
